Emergency management in patients with haemophilia A and inhibitors on prophylaxis with emicizumab: AICE practical guidance in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET.

G, Castaman; C, Santoro; A, Coppola; ME, Mancuso; RC, Santoro; S, Bernardini; FR, Pugliese; R, Lubrano; M, Golato; A, Tripodi; A, Rocino; E, Santagostino; C, Biasoli; A, Borchiellini; A, Catalano; L, Contino; A, Coluccia; D, Cultrera; Cristofaro R, De; Minno G, Di; A, Fabbri; M, Franchini; G, Gamba; AC, Giuffrida; P, Gresele; A, Giampaolo; HJ, Hassan; M, Luciani; E, Marchesini; R, Marino; MG, Mazzucconi; AC, Molinari; M, Morfini; LD, Notarangelo; L, Peccarisi; F, Peyvandi; B, Pollio; GF, Rivolta; MP, Ruggieri; V, Sargentini; M, Schiavoni; L, Sciacovelli; ML, Serino; S, Siragusa; A, Tagliaferri; S, Testa; A, Tosetto; S, Zampogna; E, Zanon

doi:10.2450/2019.0186-19

Public

Emergency management in patients with haemophilia A and inhibitors on prophylaxis with emicizumab: AICE practical guidance in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET.

Shared by NobleBlocks on Oct 18, 2019 • 12:00 AM UTC

Authors:

Castaman G

Santoro C

Coppola A

Abstract

Emicizumab has been approved in several countries for regular prophylaxis in patients with congenital haemophilia A and FVIII inhibitors because it substantially reduces their bleeding risk and improves quality of life. However, although significantly less frequent, some breakthrough bleeds may stil...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!